Tumor-targeted RNA-interference: functional non-viral nanovectors - PubMed (original) (raw)

Tumor-targeted RNA-interference: functional non-viral nanovectors

Xinghua Pan et al. Am J Cancer Res. 2011.

Abstract

While small interfering RNA (siRNA) and microRNA (miRNA) have attracted extensive attention and showed significant promise for the study, diagnosis and treatment of human cancers, delivering siRNA or miRNA specifically and efficiently into tumor cells in vivo remains a great challenge. Delivery barriers, which arise mainly from the routes of administration associated with complex physiochemical microenvironments of the human body and the unique properties of RNAs, hinder the development of RNA-interference (RNAi)-based therapeutics in clinical practice. However, in available delivery systems, non-viral nanoparticle-based gene/RNA-delivery vectors, or nanovectors, are showing powerful delivery capacities and huge potential for improvements in functional nanomaterials, including novel fabrication approaches which would greatly enhance delivery performance. In this review, we summarize the currently recognized RNAi delivery barriers and the anti-barrier requirements related to vectors' properties. Recent efforts and achievements in the development of novel nanomaterials, nanovectors fabrication methods, and delivery approaches are discussed. We also review the outstanding needs in the areas of material synthesis and assembly, multifunction combinations, proper delivery and assisting approaches that require more intensive investigation for the comprehensive and effective delivery of RNAi by non-viral nanovectors.

Keywords: Nanoparticles; RNAi; cancer therapy; miRNA; siRNA; tumor-targeting.

PubMed Disclaimer

Similar articles

• RNAi-based therapeutics and tumor targeted delivery in cancer.
  Kara G, Calin GA, Ozpolat B. Kara G, et al. Adv Drug Deliv Rev. 2022 Mar;182:114113. doi: 10.1016/j.addr.2022.114113. Epub 2022 Jan 19. Adv Drug Deliv Rev. 2022. PMID: 35063535 Review.
• In vivo application of RNA interference: from functional genomics to therapeutics.
  Lu PY, Xie F, Woodle MC. Lu PY, et al. Adv Genet. 2005;54:117-42. doi: 10.1016/S0065-2660(05)54006-9. Adv Genet. 2005. PMID: 16096010 Free PMC article. Review.
• RNA interference (RNAi)-based plasmonic nanomaterials for cancer diagnosis and therapy.
  Yoon J, Shin M, Lee JY, Lee SN, Choi JH, Choi JW. Yoon J, et al. J Control Release. 2022 Feb;342:228-240. doi: 10.1016/j.jconrel.2022.01.012. Epub 2022 Jan 10. J Control Release. 2022. PMID: 35016917 Review.
• Encapsulation of miRNA and siRNA into Nanomaterials for Cancer Therapeutics.
  Zare M, Pemmada R, Madhavan M, Shailaja A, Ramakrishna S, Kandiyil SP, Donahue JM, Thomas V. Zare M, et al. Pharmaceutics. 2022 Aug 3;14(8):1620. doi: 10.3390/pharmaceutics14081620. Pharmaceutics. 2022. PMID: 36015246 Free PMC article. Review.
• Cationic liquid crystalline nanoparticles for the delivery of synthetic RNAi-based therapeutics.
  Gentile E, Oba T, Lin J, Shao R, Meng F, Cao X, Lin HY, Mourad M, Pataer A, Baladandayuthapani V, Cai D, Roth JA, Ji L. Gentile E, et al. Oncotarget. 2017 Jul 18;8(29):48222-48239. doi: 10.18632/oncotarget.18421. Oncotarget. 2017. PMID: 28637023 Free PMC article.

Cited by

• Cancer stem cells and drug resistance: the potential of nanomedicine.
  Vinogradov S, Wei X. Vinogradov S, et al. Nanomedicine (Lond). 2012 Apr;7(4):597-615. doi: 10.2217/nnm.12.22. Nanomedicine (Lond). 2012. PMID: 22471722 Free PMC article. Review.
• Comparison of non-coding RNAs in human and canine cancer.
  Wagner S, Willenbrock S, Nolte I, Murua Escobar H. Wagner S, et al. Front Genet. 2013 Apr 8;4:46. doi: 10.3389/fgene.2013.00046. eCollection 2013. Front Genet. 2013. PMID: 23579348 Free PMC article.
• 1,8-Naphthalimide-Based Multifunctional Compounds as Cu2+ Probes, Lysosome Staining Agents, and Non-viral Vectors.
  Gao YG, Liu FL, Patil S, Li DJ, Qadir A, Lin X, Tian Y, Li Y, Qian AR. Gao YG, et al. Front Chem. 2019 Sep 10;7:616. doi: 10.3389/fchem.2019.00616. eCollection 2019. Front Chem. 2019. PMID: 31552230 Free PMC article.
• Function of chloride intracellular channel 1 in gastric cancer cells.
  Ma PF, Chen JQ, Wang Z, Liu JL, Li BP. Ma PF, et al. World J Gastroenterol. 2012 Jun 28;18(24):3070-80. doi: 10.3748/wjg.v18.i24.3070. World J Gastroenterol. 2012. PMID: 22791942 Free PMC article.
• Therapeutic potential of chemically modified siRNA: Recent trends.
  Selvam C, Mutisya D, Prakash S, Ranganna K, Thilagavathi R. Selvam C, et al. Chem Biol Drug Des. 2017 Nov;90(5):665-678. doi: 10.1111/cbdd.12993. Epub 2017 May 16. Chem Biol Drug Des. 2017. PMID: 28378934 Free PMC article. Review.

References

1. 1. Oliveira S, Storm G, Schiffelers RM. Targeted delivery of siRNA. J Biomed Biotechnol. 2006;2006(4):63675. - PMC - PubMed
2. 1. Kim DH, Rossi JJ. Strategies for silencing human disease using RNA interference. Nat Rev Genet. 2007;8:173–184. - PubMed
3. 1. Juliano R, Alam MR, Dixit V, Kang H. Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Nucleic Acids Res. 2008;36:4158–4171. - PMC - PubMed
4. 1. Kurreck J. RNA Interference: From Basic Research to Therapeutic Applications. Angew Chem Int Ed Engl. 2009;48:1378–1398. - PMC - PubMed
5. 1. Hede K. Blocking cancer with RNA interference moves toward the clinic. J Natl Cancer Inst. 2005;97:626–628. - PubMed

Grants and funding

• R01 CA121830-04S1/CA/NCI NIH HHS/United States
• R01 CA121830/CA/NCI NIH HHS/United States
• R21 CA128220-02/CA/NCI NIH HHS/United States
• R01 CA134655-02/CA/NCI NIH HHS/United States
• R01 CA121830-05/CA/NCI NIH HHS/United States
• R21 CA128220/CA/NCI NIH HHS/United States
• R01 CA121830-04/CA/NCI NIH HHS/United States
• R01 CA134655/CA/NCI NIH HHS/United States

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • PubMed Central